Document:

EXHIBIT
10.2

 

AMENDED
AND RESTATED ASSET PURCHASE AND LICENSE AGREEMENT

 

THIS
AMENDED AND RESTATED ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) dated as of the last date provided on
the signature page (the “Restatement Date”), is entered into between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation
(“Imprimis”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and SURFACE
Pharmaceuticals, Inc., a Delaware corporation (“Surface”), with a place of business at 12264 El Camino Real,
Suite 350, San Diego, California 92130.

 

WHEREAS,
the parties entered into the Asset Purchase and License Agreement (the “Original Agreement”) effective September 28,
2017 (the “Effective Date”); and

 

WHEREAS,
the parties now desire to amend the Original Agreement in certain respects and for convenience to restate the Original Agreement,
on the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereby amend and restate the Original Agreement, and otherwise
agree, as follows effective as of the Effective Date:

 

1.
Definitions. For the purposes of this
Agreement, the following terms shall have the respective meanings set forth below and grammatical variations of such terms shall
have corresponding meanings:

 

1.1
“Affiliate” shall mean, with respect to any Person, any other Person which directly or indirectly controls,
is controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if
it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest of
the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies
of the other Person by any means whatsoever. Notwithstanding the foregoing, for purposes of this Agreement, neither Imprimis nor
Surface shall be Affiliates of the other or the other’s Affiliates.

 

1.2
“Assets” shall mean, collectively, (a) all Technology as of the Effective Date, (b) the Assigned Patent Rights,
(c) the Assigned Know-How Rights, and (d) all compositions, formulations, samples, data and information in Imprimis’ control
as of the Effective Date regarding the Technology.

 

1.3
“Assigned Know-How Rights” shall mean all trade secret and other know-how rights specific to the Technology
owned by Imprimis as of the Effective Date.

 

1.4
“Assigned Patent Rights” shall mean, collectively, (a) all patent applications (including provisional patent
applications) listed on Schedule A, together with all divisionals, continuations and continuations-in-part that claim priority
to, or common priority with, the foregoing; (b) all patents issuing therefrom (including utility models and design patents and
certificates of invention), together with all reissues, renewals, extensions or additions thereof and thereto; and (c) all foreign
counterparts with or to any of the foregoing.

 

    	 	1	 

    	 

    

 

1.5
“Confidential Information” shall mean all information and data that (a) is provided by one party to the other
party under this Agreement, and (b) if disclosed in writing or other tangible medium is marked or identified as confidential at
the time of disclosure to the recipient, is acknowledged at the time of disclosure to be confidential, or otherwise should reasonably
be deemed to be confidential. Imprimis’ Confidential Information includes, without limitation, embodiments of the Licensed
Know-How Rights. Surface’s Confidential Information includes, without limitation, the Assets. Notwithstanding the foregoing,
Confidential Information of a party shall not include that portion of such information and data which, and only to the extent,
the recipient can establish by written documentation: (a) is known to the recipient as evidenced by its written records before
receipt thereof from the disclosing party, (b) is disclosed to the recipient free of confidentiality obligations by a third person
who has the right to make such disclosure, (c) is or becomes part of the public domain through no fault of the recipient, or (d)
the recipient can reasonably establish is independently developed by persons on behalf of recipient without access to or use of
the information disclosed by the disclosing party. For clarity, the Assets shall be the Confidential Information of Surface notwithstanding
the fact that such information originated with Imprimis and notwithstanding exception (a) above.

 

1.6
“Control” and its correlative terms, “Controlled” or “Controls” shall
mean, with respect to any patent, patent application, item of know-how or other intellectual property, that a party owns or has
a license or sublicense to such item or right, and has the ability to grant the access, license or sublicense contemplated by
this Agreement in or to such item or right without violating the terms of any agreement or other arrangement with any Third Party.

 

1.7
“FDA” shall mean the Food and Drug Administration of the United States, or any successor thereto.

 

1.8
“First Commercial Sale” shall mean, with respect to any Product, the first sale of such Product after all applicable
marketing and pricing approvals (if any) have been granted by the applicable governing health authority.

 

1.9
“Imprimis Field” shall mean drug products compounded or manufactured in compounding pharmacies or outsourcing
facilities as defined and outlined in the Federal Food, Drug & Cosmetic Act (21 U.S.C §353a and 21 U.S.C. §353b).

 

1.10
“IND” shall mean an investigational new drug application filed with the FDA for approval to commence human
clinical trials and any successor form thereto and/or its equivalent in other jurisdictions.

 

1.11
“Licensed Know-How Rights” shall mean all trade secret or other know-how rights Controlled by Imprimis as of
the Effective Date regarding the Technology, but excluding the Assigned Know-How Rights and Assigned Patent Rights.

 

    	 	2	 

    	 

    

 

1.12
“Licensed Patent Rights” shall mean (a) the patents and patent applications listed on Schedule B, (b) all worldwide
patents and patent applications that claim or cover the Product, or derivatives, enhancements, improvements and other modifications
thereof, or methods of manufacture or uses of any of the foregoing, that share common priority date with the patents and patent
applications listed on Schedule B, in each case, which Imprimis heretofore or hereafter Controls, (c) all divisions, continuations,
continuations-in-part, that claim priority to, or common priority with, the patent applications described in clauses (a) and (b)
above or the patent applications that resulted in the patents described in clauses (a) and (b) above, (d) all patents that have
issued or in the future issue from any of the foregoing described patent applications, including utility model, and (e) all extensions,
supplemental protection certificates, registrations, confirmations, reissues, reexaminations, inter partes reviews, post-grant
reviews, restorations, additions and renewals of or to any of the foregoing described patents.

 

1.13
“Licensee” shall mean a Third Party to whom Surface or its Affiliate has granted a (sub)license, immunity or
other right under the Assigned Patent Rights or Licensed Patent Rights to offer to sell, sell or otherwise commercialize one or
more Products, provided such license has not expired or been terminated.

 

1.14
“Lindstrom License Agreement” shall mean that certain Amended and Restated License Agreement between Richard
L. Lindstrom, M.D. (“Lindstrom”) and Imprimis, of approximately even date herewith.

 

1.15
“Net Licensing Revenues” shall mean, with respect to any Product, the aggregate cash payment (or equity received
in lieu of cash payments) received by Surface or its Affiliates as consideration for the grant by Surface or its Affiliates to
a Licensee of a license, immunity or other right under the Assigned Patent Rights to offer to sell, sell or otherwise commercialize
such Product, excluding: (a) amounts calculated on the sales price of such Product, (b) debt financing; (c) equity investments
(and conditional equity, such as warrants, convertible debt) in Surface at market value; (d) reimbursements of patent prosecution
costs and patent maintenance expenses; (e) withholding taxes and other amounts actually withheld from or deducted against the
amounts paid to such party; (f) amounts received from Licensee for commercial manufacturing of goods if sales of such goods are
already subject to an earned royalty; and (g) amounts received as payment or reimbursement for research, development and/or other
services conducted by or for Licensee, including costs of materials, equipment, manufacturing services or clinical testing, e.g.,
provided on the basis of full-time equivalent efforts of personnel at or below commercially reasonable and standard FTE rates
and/or the reimbursement of out-of-pocket expenses.

 

1.16
“Net Receipts” shall mean, with respect to any Product, the aggregate of the Net Sales thereof and Net Licensing
Revenues therefrom.

 

1.17
“Net Sales” shall mean, with respect to any Product, the gross sales price for such Product invoiced by Surface,
or its Affiliates or its or their respective Licensees to Third Parties, less (a) credits, allowances, discounts and rebates to,
and chargebacks from the account of, such customers; (b) freight and insurance costs in transporting such Product to the extent
separately invoiced and included in the gross sales price; (c) cash, quantity and trade discounts, rebates and other price reductions
for such Product; (d) sales, use, value-added and other direct taxes for such Product to the extent separately invoiced and included
in the gross sales price; (e) customs duties, tariffs, surcharges and other governmental charges incurred in exporting or importing
such Product to the extent separately invoiced and included in the gross sales price; and (f) an allowance for uncollectible or
bad debts for such Product determined in accordance with generally accepted accounting principles not to exceed three percent
(3%) of Net Sales of such Product for the applicable quarterly reporting period before giving effect to this subsection (f). For
clarity, the amounts received for the transfer of Product by Surface to and among its Affiliates and Licensees for resale shall
be excluded from the computation of Net Sales, but the subsequent resale of such Product to a Third Party (that is not a Licensee)
shall be included within the computation of Net Sales.

 

    	 	3	 

    	 

    

 

Disposal
of Product for or use in clinical trials, as free samples, or under compassionate use, patient assistance, named patient or test
marketing programs or non-registrational studies or other similar programs or studies or testing, shall not result in any Net
Sales under this Section to the extent the amounts received for such Product do not exceed manufacturing cost.

 

If
any Product is sold as part of a combination product (being a product containing both a Product and one or more active ingredients
or a product in which both Product and one or more active ingredients are packaged), the Net Sales from the combination product,
for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the combination product
(as defined in the standard Net Sales definition), during the applicable royalty period, by the fraction, A/(A+B), where A is
the average per unit sale price of Product when sold separately as a stand-alone product in finished form in the country in which
the combination product is sold and B is the average per unit sale of the other active ingredients contained in the combination
product when sold separately as stand-alone products in finished form in the country in which the combination product is sold,
in each case during the applicable royalty reporting period or, if sales of stand-alone Product did not occur in such period,
then in the most recent royalty reporting period in which arms-length fair market sales of such Products, as applicable, occurred.
If such average sale price cannot be determined for the stand-alone Products or the other products, Net Sales for the purposes
of determining royalty payments shall be mutually agreed upon by the Parties based on the relative value contributed by each component.

 

1.18
“Patent Issuance” shall mean issuance of a patent from, claiming priority to, or claiming common priority with,
a patent application listed on Schedule A, or any foreign counterpart of the foregoing.

 

1.19
“Person” shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization
or other entity, as well as any syndicate or group of any of the foregoing.

 

1.20
“Product” shall mean any product, in a topical eyedrop formulation, that if made, used, offered for sale, sold
or imported would infringe a Valid Claim within the Assigned Patent Rights (if such Valid Claim were in an issued patent and not
owned by Surface).

 

1.21
“Product Supported Patent Rights” shall mean, collectively, (a) all patent applications hereafter filed anywhere
in the world claiming inventions made within five (5) years after the Effective Date by Surface or Imprimis; (b) all patents that
have issued or in the future issue from any of the foregoing patent applications, including without limitation utility models,
design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patents and patent applications; in each case that use or are supported by data and information
derived from the development, manufacture or use of a Product by either party in their respective fields; provided, however, that
Product Supported Patent Rights shall exclude the Assigned Patent Rights.

 

    	 	4	 

    	 

    

 

1.22
“Regulatory Exclusivity” shall mean, with respect to any country or other jurisdiction, an additional market
protection, other than patent protection, granted by a regulatory authority in such country or other jurisdiction which confers
an exclusive commercialization period during which Surface or its Affiliates or Licensees have an exclusive right to market and
sell a Product in such country or other jurisdiction through a regulatory exclusivity right (including regulatory data exclusivity).

 

1.23
“Royalty Term” shall mean with respect to a given Product in a given country, the later of:

 

1.23.1
ten (10) years from the First Commercial Sale of the first Product in such country, and

 

1.23.2
the later of (a) expiration of the last to expire Valid Claim in such country of the Assigned Patent Rights covering such Product,
and (b) expiration of any Regulatory Exclusivity with respect to such Product in such country.

 

1.24
“Surface Field” shall mean all fields of use other than the Imprimis Field.

 

1.25
“Technology” shall mean, collectively, the Product together with all methods of manufacture or use thereof.

 

1.26
“Third Party” shall mean any Person other than Imprimis, Surface or their respective Affiliates.

 

1.27
“Valid Claim” shall mean either (a) a claim of an issued and unexpired patent included within the Assigned
Patent Rights, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted
to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application included
within the Assigned Patent Rights, which claim was filed in good faith and has not been abandoned or finally disallowed without
the possibility of appeal or refiling of such application.

 

2.
Purchase and Sale of the Assets.

 

2.1
Assets. Subject to the terms and conditions of this Agreement, Surface hereby purchases from Imprimis, and Imprimis hereby
sells, conveys, transfers and assigns to Surface, on the Effective Date, all of Imprimis’ right, title and interest in and
to the Assets. To the extent necessary to comply with applicable privacy laws, Imprimis shall have the right to redact patient
identifying information from any data or information transferred to Surface.

 

    	 	5	 

    	 

    

 

2.2
No Assumption of Liabilities. Surface shall not be obligated to assume or perform and is not assuming or performing any
liabilities or obligations of Imprimis which relate to Imprimis’ ownership of the Assets prior to the Effective Date or
otherwise, whether known or unknown, fixed or contingent, certain or uncertain, and regardless of when they are or were asserted,
and Imprimis shall remain responsible for such liabilities.

 

2.3
Transfer Documents. The sale, conveyance, transfer and assignment of the Assets may be further evidenced by the due execution
and delivery by the parties of any additional bills of sale, assignment or other title transfer documents and instruments as reasonably
requested by Surface evidencing the sale, conveyance, transfer and assignment of the Assets in accordance with this Agreement.

 

3.
License Grants.

 

3.1
License to Surface.

 

3.1.1
Subject to the terms and conditions of this Agreement, Imprimis hereby grants to Surface a non-exclusive non-transferable (except
in connection with a permitted assignment of this Agreement), worldwide (sub)license under the Licensed Patent Rights and Licensed
Know-How Rights to develop, make, have made, use, offer for sale, sell, and import (a) Products in the Surface Field, and (b)
any other product(s) in a topical eyedrop formulation, that (i) would infringe the Licensed Patent Rights (if such Licensed Patent
Rights were not licensed to Surface), and (ii) contain one or more additional active ingredients not claimed in the Licensed Patent
Rights (including without limitation mycophenolic acid, cyclosporine, betamethasone, albumin, plasma, platelet rich plasma, serum
or derivatives or analogs thereof), in each case solely in the Surface Field.

 

3.1.2
Surface shall have the right to grant sublicenses, through multiple tiers, to Third Parties and Affiliates for the purpose of
developing, manufacturing, seeking regulatory approval for, or commercializing any products described in 3.1.1(a) or (b) in the
Surface Field. Any such sublicense shall be subject and subordinate to the terms and conditions of this Agreement.

 

3.1.3
The licenses granted to Surface pursuant to Section 3.1.1 above shall be perpetual and irrevocable, provided that it is understood
and acknowledged that with respect to the Licensed Patent Rights and Licensed Know-How licensed to Imprimis under the Lindstrom
License Agreement, Imprimis’ ability to maintain the license granted to Surface under Section 3.1.1 with respect to such
Licensed Patent Rights and Licensed Know-How is contingent upon Imprimis’ continued maintenance of the Lindstrom License
Agreement in full force and effect. Accordingly, Imprimis agrees that it will use its best efforts to maintain in full force and
effect the Lindstrom License Agreement. Without limiting the foregoing, Imprimis covenants that during the term of this Agreement,
Imprimis shall not (a) amend or otherwise modify or permit to be amended or modified the Lindstrom License Agreement, in each
case in a manner that would encumber or diminish the rights granted to Surface hereunder, or (b) grant to any Third Party any
rights under the Lindstrom License Agreement that would conflict with or otherwise diminish the rights granted to Surface hereunder.

 

    	 	6	 

    	 

    

 

3.2
Grantback Licenses

 

3.2.1
Subject to the terms and conditions of this Agreement, Surface hereby grants to Imprimis a non-exclusive, irrevocable, perpetual,
non-transferable (except in connection with a permitted assignment of this Agreement), worldwide license under:

 

(a)
the Assigned Patent Rights for purposes of making, using, selling, offering for sale and importing Products in the Imprimis Field
(subject to the limitations contained in Section 6.2.3) and

 

(b)
the Product Supported Patent Rights Controlled by Surface (i) in the Imprimis Field (subject to the limitations contained in Section
6.2.3), and (ii) for purposes of making, using, selling, offering for sale and importing non-combination medical device cleared
under Section 510(k) of the Federal Food, Drug & Cosmetic Act. For clarity, the license granted pursuant to subsection (ii)
expressly excludes the right to make, use, sell, offer for sale or import the products described in 3.1.1(a) or (b).

 

3.2.2
Subject to the terms and conditions of this Agreement, Imprimis hereby grants to Surface a non-exclusive, irrevocable, perpetual,
non-transferable (except in connection with a permitted assignment of this Agreement), worldwide license under the Product Supported
Patent Rights Controlled by Imprimis solely for purposes of making, using, selling, offering for sale and importing products described
in 3.1.1(a) or (b) in the Surface Field.

 

3.2.3
Imprimis shall have the right to grant sublicenses, through multiple tiers, to Third Parties and Affiliates under the license
granted to pursuant to Section 3.2.1. Surface shall have the right to grant sublicenses, through multiple tiers, to Third Parties
and Affiliates under the license granted to pursuant to Section 3.2.2.

 

3.3
No Implied Licenses. Only licenses and rights expressly granted herein shall be of legal force and effect. No license or
other right shall be created hereunder by implication, estoppel, or otherwise.

 

4.
Representations and Warranties.

 

4.1
Mutual Representations and Warranties. Each party represents and warrants to the other party as follows:

4.1.1
Organization. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in
which it is organized.

 

4.1.2
Authorization and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize
the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed
and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance
with its terms.

 

    	 	7	 

    	 

    

 

4.1.3
Consents. All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities
required to be obtained by such party in connection with this Agreement have been obtained.

 

4.1.4
No Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b)
do not conflict with, or constitute a default under, any contractual obligation of such party.

 

4.2
Disclaimer of Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION
4.1, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE ASSETS, LICENSED PATENT RIGHTS,
LICENSED KNOW-HOW RIGHTS, OR ANY OTHER MATTER, INCLUDING WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY REGARDING VALIDITY,
ENFORCEABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT. THE ASSETS, LICENSED PATENT RIGHTS, AND
LICENSED KNOW-HOW RIGHTS ARE PROVIDED “AS IS.”

 

 

5.
Financial Terms.

 

5.1
Milestone Payment. Within thirty (30) days following the first Patent Issuance, Surface shall give written notice to Imprimis
and shall pay to Imprimis a non-refundable and noncreditable payment of fifty thousand dollars ($50,000).

 

5.2
Lindstrom Royalties. In connection with the execution of this Agreement, Surface has entered into a written agreement (“Royalty
Agreement”) with Richard L. Lindstrom, an individual, pursuant to which Surface shall pay to Richard L. Lindstrom, on a
Product-by-Product basis, three percent (3%) of Net Sales on terms and conditions set forth therein. A copy of the Royalty Agreement
is attached hereto as Schedule C.

 

5.3
Net Receipts Payments.

 

5.3.1
Net Receipts Payment Amounts.

 

(a)
Payment Amount. Subject to the provisions in this Section 5.3.1, on a Product-by-Product and country-by-country basis,
Surface shall pay to Imprimis, on a quarterly basis for the duration of the Royalty Term, four percent (4%) of Net Receipts (the
“Payment Amount”); provided, however, if, the manufacture, use, offer for sale, sale, or import of such Product
in a particular country would not infringe a Valid Claim (if such Valid Claim were in an issued patent and not owned by or licensed
to Surface) and is not subject to Regulatory Exclusivity, then the applicable Payment Amount with respect to such Product in such
country shall be reduced by one-half (1⁄2).

 

(b)
Third Party Royalties. If Surface, its Affiliate or its or their respective Licensee is required to pay a Third Party (other
than Richard L. Lindstrom) amounts with respect to a Product under agreements for patent rights or other technologies which Surface,
its Affiliate or its or their respective Licensee determines are necessary or desirable to license or acquire with respect to
such Product, Surface may deduct such amount owing to such Third Parties (prior to any reductions) from the royalty owing to Imprimis
pursuant to Section 5.3.1(a) above. Notwithstanding the foregoing provisions of this Section 5.3.1(b), in no event shall the royalties
due to Imprimis pursuant to Section 5.3.1(a) above be so reduced to less than fifty percent (50%) of the amount that would otherwise
be due Imprimis thereunder.

 

    	 	8	 

    	 

    

 

(c)
Discounts. If Surface, its Affiliates, or its or their respective Licensees sells the Product to a Third Party who also
purchases other products or services from Surface, its Affiliates, or its or their respective Licensees, and Surface, its Affiliates,
or its or their respective Licensees discounts the purchase price of the Product to a greater degree than it generally discounts
the price of its other products or services to such customer, then in such case the Net Sales for the sale of the Product to such
Third Party shall equal the arm’s length price that Third Parties would generally pay for the Product alone when not purchasing
any other product or service from Surface, its Licensees, or its or their respective Licensees. For purposes of this provision,
“discounting” includes establishing the list price at a lower-than-normal level.

 

(d)
Incentives. If Surface, its Affiliates, or its or their respective Licensees sells the Product to a Third Party who also
purchases other products or services from Surface, its Affiliates, or its or their respective Licensees during the same period
pursuant to a pharmacy, performance or other incentive program, a disease management or similar program, or any other discount,
chargeback or credit program for products or services purchased, then for purposes of calculating Net Sales of the Product hereunder
for such period, all discounts, chargebacks, credits and the like for such Third Party shall be allocated in proportion to the
respective list prices of all products or services sold to such Third Party during such period.

 

5.3.2
Reports and Net Receipts Payments. Within sixty (60) days after the end of each calendar quarter, Surface shall deliver
to Imprimis a report setting forth for such calendar quarter (a) the calculation of the applicable Payment Amount; (b) the payments
due under this Agreement for the sale of each Product; and (c) the applicable exchange rate as determined below. Surface shall
remit the total payments due for the sale of Products during such calendar quarter at the time such report is made. No such reports
or payments shall be due for any Product before the First Commercial Sale of such Product. With respect to Net Receipts received
in United States dollars, all amounts shall be expressed in United States dollars. With respect to Net Receipts received in a
currency other than United States dollars, all amounts shall be expressed both in the currency in which the amount is invoiced
(or received as applicable) and in the United States dollar equivalent. The United States dollar equivalent shall be calculated
using the average of the exchange rate (local currency per US$1) published in The Wall Street Journal, Western Edition,
under the heading “Currency Trading” on the last business day of each month during the applicable calendar quarter.

 

5.4
Payment Provisions.

 

5.4.1
Payment Method. All payments by Surface to Imprimis hereunder shall be in United States dollars in immediately available
funds and shall be made by wire transfer from a United States bank located in the United States to such bank account as designated
from time to time by Imprimis to Surface.

 

    	 	9	 

    	 

    

 

5.4.2
Payment Terms. The Payment Amount shown to have accrued by each report provided for under Section 5.3.2 shall be due on
the date such report is due. Payment of Payment Amount in whole or in part may be made in advance of such due date.

 

5.4.3
Withholding Taxes. Surface shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other
taxes, levies or charges with respect to such amounts, other than United States taxes, payable by Surface, its Affiliates, or
its or their respective Licensees, or any taxes required to be withheld by Surface, its Affiliates, or its or their respective
Licensees, to the extent Surface, its Affiliates, or its or their respective Licensees pay to the appropriate governmental authority
on behalf of Imprimis such taxes, levies or charges. Surface shall use reasonable efforts to minimize any such taxes, levies or
charges required to be withheld on behalf of Imprimis by Surface, its Affiliates, or its or their respective Licensees. Surface
promptly shall deliver to Imprimis proof of payment of all such taxes, levies and other charges, together with copies of all communications
from or with such governmental authority with respect thereto.

 

5.5
Audits. Upon the written request of Imprimis and not more than once in each calendar year, Surface shall permit an independent
certified public accounting firm selected by Imprimis and reasonably acceptable to Surface, at Imprimis’ expense, to have
access during normal business hours to such of the financial records of Imprimis as may be reasonably necessary to verify the
accuracy of the Payment Amount reports hereunder for the eight (8) calendar quarters immediately prior to the date of such request.
If such accounting firm concludes that additional amounts were owed during the audited period, Surface shall pay such additional
amounts within thirty (30) days after the date Imprimis delivers to Surface such accounting firm’s written report so concluding.
The fees charged by such accounting firm shall be paid by Imprimis; provided, however, if the audit discloses that the Payment
Amount payable by Surface for such period are more than one hundred five percent (105%) of the Payment Amount actually paid for
such period, then Surface shall pay the fees and expenses charged by such accounting firm. Imprimis shall cause its accounting
firm to retain all financial information subject to review under this Section 5.5 in strict confidence. Imprimis shall treat all
such financial information as Surface’s confidential information, and shall not disclose such financial information to any
Third Party or use it for any purpose other than as specified in this Section 5.5.

 

6.
Post-Effective Date Covenants.

 

6.1
Surface Diligence.

 

6.1.1
Surface shall use commercially reasonable efforts (whether alone or with or through its Licensees and its or their respective
Affiliates) to research, develop and commercialize Products.

 

6.1.2
Surface shall control, at its sole expense, the preparation, filing, prosecution, maintenance and enforcement of the Assigned
Patent Rights consistent with prudent business practices, and shall consider in good faith the interests of Imprimis.

 

6.2
Imprimis Covenants.

 

6.2.1
Within thirty (30) days after the Effective Date, Imprimis shall transfer to Surface all tangible embodiments of the Technology
in the possession and control of Imprimis.

 

    	 	10	 

    	 

    

 

6.2.2
Imprimis shall provide cooperation reasonably requested by Surface in connection with Surface’s efforts to establish, perfect,
defend, or enforce its rights in or to the Assets (including without limitation the Assigned Patent Rights). Such cooperation
shall include, without limitation, (a) executing such further assignments, transfers, licenses, releases and consents, and (b)
providing such data and information, consulting with Surface and executing and delivering all such further documents and instruments,
in each case as reasonably requested by Surface regarding the Assets (including without limitation the Assigned Patent Rights).

 

6.2.3
Notwithstanding anything in this Agreement to the contrary, for the period commencing on the date thirty (30) days after the First
Commercial Sale of a Product and continuing until such time as Surface, its Affiliates and its or their respective Licensees (or
their successors) cease for at least twenty-four (24) months all bona fide development or commercialization of such Product, Imprimis
shall refrain from compounding pharmaceutical products containing the same active ingredient as contained in such Product (or
if there is more than one active ingredient contained in a given Product, then the same combination of active ingredients as is
contained in such Product) in the Surface Field; provided however, within 30 days of the filing of an IND for a drug candidate
containing mycophenolic acid or betamethasone, Surface shall retain the right to demand Imprimis cease production and selling
of any topical eye drop products containing mycophenolic acid or betamethasone, and Imprimis shall comply with such demand within
90 days thereafter.

 

7.
Indemnification.

 

7.1
Indemnification of Surface. Subject to the provisions of this Section 7, Imprimis shall indemnify, defend and hold harmless
Surface, its officers, directors, affiliates, agents, stockholders and representatives (collectively, the “Surface Indemnitees”),
from and against any and all losses, liabilities, damages and expenses (including without limitation reasonable attorneys’
fees and costs) incurred as a result of any claim, demand, action or proceeding by any Third Party (collectively, “Losses”)
incurred or suffered by an Surface Indemnitee to the extent arising out of:

 

7.1.1
any breach of the representations and warranties of Imprimis set forth in this Agreement;

 

7.1.2
any breach of any covenant or agreement of Imprimis set forth in this Agreement or in any certificate, instrument, or other document
delivered pursuant to this Agreement;

 

7.1.3
the ownership or exploitation of the Assets prior to the Effective Date or any liability or obligation whatsoever of Imprimis;
and

 

    	 	11	 

    	 

    

 

7.1.4
the development, manufacture, use, or sale of any product described in 3.1.1(a) or (b) solely by Imprimis, its Affiliates or their
respective Licensees or the use of any such product by their customers.

 

7.2
Indemnification of Imprimis. Subject to the provisions of this Section 7, Surface shall indemnify and hold harmless Imprimis,
its officers, directors, affiliates, agents, stockholders and representatives (collectively, the “Imprimis Indemnitees”),
from and against any and all Losses incurred or suffered by an Imprimis Indemnitee to the extent arising out of:

 

7.2.1
any breach of the representations and warranties of Surface set forth in this Agreement;

7.2.2
any breach of any covenant or agreement of Surface set forth in this Agreement or in any certificate, instrument, or other document
delivered pursuant to this Agreement;

 

7.2.3
the ownership or exploitation of the Assets after the Effective Date (other than the exploitation of the Assigned Patent Rights
and Product Supported Patent Rights by Imprimis subject to its grantback license) or the manufacture, use, or sale of any product
described in 3.1.1(a) or (b) solely by Surface, its Affiliates or their respective Licensees or the use of any such product by
their customers.

 

7.3
Procedure. A party seeking indemnification (the “Indemnitee”) shall promptly notify the other party
(the “Indemnifying Party”) in writing of a claim or suit; provided that an Indemnitee’s failure to give
such notice or delay in giving such notice shall not affect such Indemnitee’s right to indemnification under this Section
7 except to the extent that the Indemnifying Party has been prejudiced by such failure or delay. The Indemnifying Party shall
have the right to control the defense of all indemnification claims hereunder. The Indemnitee shall have the right to participate
at its own expense in the claim or suit with counsel of its own choosing. The Indemnifying Party shall consult with the Indemnitee
in good faith with respect to all non-privileged aspects of the defense strategy. The Indemnitee shall cooperate with the Indemnifying
Party as reasonably requested, at the Indemnifying Party’s sole cost and expense. The Indemnifying Party shall not settle
any claim or suit without the Indemnitee’s prior written consent, which consent shall not be unreasonably withheld.

 

8.
Confidentiality.

 

8.1
Confidential Information. Following the Effective Date and for a period of five (5) years after the expiration of the last
Valid Claim, except as otherwise provided in this Section 8, each party shall maintain in confidence the Confidential Information
of the other party except as expressly permitted herein, and shall not use, disclose or grant the use of the Confidential Information
except on a need-to-know basis to those directors, officers, employees and contractors, to the extent such disclosure is reasonably
necessary in connection with performing its obligations or exercising its rights under this Agreement. To the extent that disclosure
by a party is authorized by this Agreement, prior to disclosure, such party shall obtain agreement of any such Person to hold
in confidence and not make use of the Confidential Information for any purpose other than those permitted by this Agreement.

 

    	 	12	 

    	 

    

 

8.2
Terms of this Agreement. Neither party shall disclose any terms or conditions of this Agreement to any Third Party without
the prior consent of the other party; provided, however, that a party may disclose the terms or conditions of this Agreement,
(a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary, and (b)
to a third party in connection with (i) an equity investment in such party, (ii) a merger, consolidation or similar transaction
by such party, (iii) a permitted sublicense under this Agreement, or (iv) the sale of all or substantially all of the assets of
such party. Notwithstanding the foregoing, prior to execution of this Agreement, the parties have agreed upon the substance of
information that can be used to describe the terms of this transaction, and each party may disclose such information, as modified
by mutual agreement from time to time, without the other party’s consent.

 

8.3
Permitted Disclosures. The confidentiality obligations contained in this Section 8 shall not apply to the extent that a
party is required (a) in the reasonable opinion of such party’s legal counsel, to disclose information by applicable law,
regulation, rule (including rule of a stock exchange or automated quotation system), order of a governmental agency or a court
of competent jurisdiction or legal process, including tax authorities, or (b) to disclose information to any governmental agency
for purposes of obtaining approval to test or market a product, provided in either case that, to the extent practicable, such
party shall provide written notice thereof to the other party and sufficient opportunity to object to any such disclosure or to
request confidential treatment.

 

8.4
Injunctive Relief. Each party acknowledges that it will be impossible to measure in money the damage to the other party
if such party fails to comply with the obligations imposed by this Section 8, and that, in the event of any such failure, the
other party may not have an adequate remedy at law or in damages. Accordingly, each party agrees that injunctive relief or other
equitable remedy, in addition to remedies at law or damages, is an appropriate remedy for any such failure and shall not oppose
the granting of such relief on the basis that the disclosing party has an adequate remedy at law. Each party agrees that it shall
not seek, and agrees to waive any requirement for, the securing or posting of a bond in connection with the other party seeking
or obtaining such equitable relief.

 

9.
Miscellaneous.

 

9.1
Assignment. Neither party shall assign its rights or obligations under this Agreement without the prior written consent
of the other party; provided, however, that a party may, without such consent, assign this Agreement and its rights and obligations
hereunder (a) to any Affiliate, or (b) in connection with the transfer or sale of all or substantially all of its business to
which this Agreement relates, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section
9.1 shall be void.

 

9.2
Severability. Any provision of this Agreement which is illegal, invalid or unenforceable shall be ineffective to the extent
of such illegality, invalidity or unenforceability, without affecting in any way the remaining provisions hereof.

 

    	 	13	 

    	 

    

 

9.3
Governing Law; Exclusive Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of
the State of California, without regard to the conflicts of law principles thereof. Each of the parties hereto irrevocably consents
to the exclusive jurisdiction and venue of any federal court located in the Southern District of the State of California or state
court in San Diego, California having jurisdiction, in connection with any matter based upon or arising out of this Agreement
or the matters contemplated herein, agrees that process may be served upon them in any manner authorized by laws of the State
of California for such persons and waives and covenants not to assert or plead any objection which they might otherwise have to
such jurisdiction, venue and such process.

 

9.4
Entire Agreement; Amendment. This Agreement, together with the Schedules hereto, and each additional document, instrument
or other agreement to be executed and delivered pursuant hereto constitute all of the agreements of the parties with respect to,
and supersede all prior agreements and understandings relating to the subject matter of, this Agreement or the transactions contemplated
by this Agreement. This Agreement may not be modified or amended except by a written instrument specifically referring to this
Agreement signed by the parties hereto.

 

9.5
Waiver. No waiver by one party of the other party’s obligations, or of any breach or default hereunder by any other
party, shall be valid or effective, unless such waiver is set forth in writing and is signed by the party giving such waiver;
and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature or any other breach
or default by such other party.

 

9.6
Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by a party to the
other party shall be in writing, delivered by any lawful means to such other party at its address indicated below, or to such
other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this
Agreement) shall be effective upon receipt by the addressee.

 

	 	If
    to Imprimis:  	Imprimis
    Pharmaceuticals, Inc.
	 	 	 
	 	 	12264
    El Camino Real, Suite 350
	 	 	San
    Diego, California 92130
	 	 	Attention:
    Chief Executive Officer
	 	 	 
	 	If
    to Surface:  	Surface
    Pharmaceuticals, Inc.
	 	 	12264
    El Camino Real, Suite 350
	 	 	San
    Diego, California 92130
	 	 	Attention:
    Executive Director

 

9.7
Counterparts. This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

 

***SIGNATURE
PAGE FOLLOWS***

 

    	 	14	 

    	 

    

 

SIGNATURE
PAGE

 

IN
WITNESS WHEREOF, each party has caused a duly authorized representative to execute and deliver this Agreement as of the date below.

 

	IMPRIMIS		 	 	SURFACE
	 	 	 	 	 
	Imprimis
    Pharmaceuticals, Inc.	 	 	Surface
    Pharmaceuticals, Inc.
	                           	 	 	 
	 	/s/
    Mark L. Baum	 		/s/
    Andrew R. Boll
	By:
    	Mark
    L. Baum	 	By:
    	Andrew
    R. Boll
	Its:
    	Chief
    Executive Officer	 	Its:
    	Executive
    Director
	 	 	 	 	 
	Date: 4/10/2018	Date: 4/10/2018

 

[Signature Page to Amended and Restated Asset Purchase and License Agreement] 

 

    	 	 	 

    	 

    

 

SCHEDULE
A

 

Assigned
Patent Rights

 

	SUMMARY	 	TITLE	 	INVENTOR	 	MATTER
    TYPE	 	COUNTRY	 	STATUS	 	APPLICATION
    #	 	DATE
    FILED
	Composition
    for treating dry eye etc.	 	Ophthalmic
    pharmaceutical compositions and...	 	Saadeh	 	Provisional	 	U.S.

                                                                              
	 	Pending	 	USSN
    62/562,809	 	September
    25, 2017

 

    	 	 	 

    	 

    

 

SCHEDULE
B

 

Licensed
Patent Rights

 

	TITLE	 	INVENTOR	 	MATTER
    TYPE	 	COUNTRY	 	STATUS	 	PATENT
    #	 	DATE
    FILED	 	DATE
    ISSUED
	OPHTHALMIC
    COMPOSITIONS INCLUDING LUBRICANT, DETURGESCENT AGENT, AND GLYCOSAMINOGLYCAN AND METHODS OF USING THE SAME	 	Richard
    L. Lindstrom	 	Utility	 	USA	 	Issued	 	7,820,639	 	September
    30, 2005	 	October
    26, 2010
	OPHTHALMIC
    COMPOSITIONS INCLUDING LUBRICANT, DETURGESCENT AGENT, AND GLYCOSAMINOGLYCAN AND METHODS OF USING THE SAME	 	Richard
    L. Lindstrom	 	Utility	 	USA	 	Issued	 	8,551,974	 	June
    11, 2010	 	October
    8, 2013

 

    	 	 	 

    	 

    

 

SCHEDULE
C

 

Royalty
Agreementlife-ex101_149.htm

Exhibit 10.1

September 13, 2016

 

 

David King, Ph.D.

310 Cole Ranch Road

Encinitas, CA  92024

 

 

Re: Offer of Employment

 

Dear David,

 

This letter is a formal offer setting forth the principal terms for you to join aTyr Pharma, Inc. (“aTyr” or the “Company”), a Delaware corporation, which is located in San Diego, California.  

 

	
Position:
	
Sr. Vice President, Research

 

	
Location:
	
San Diego, CA

 

	
Status:
	
Full-Time, Exempt.  This means you are paid for the job and not by the hour.  Accordingly, you will not receive overtime pay if you work more than 8 hours in a work day or 40 hours in a workweek.

 

Reporting to:John D. Mendlein, Ph.D., Chief Executive Officer

 

	
Base Salary Rate:
	
$12,083.34 semi-monthly (which equals $290,000.16 per year) less applicable withholdings, paid in accordance with Company’s normal payroll practices during your Full-Time employment.  Future adjustments in compensation, if any, will be made by the Company in its sole and absolute discretion.

 

	
Target Bonus:
	
Your annual target bonus will be 35% of your base salary based upon the achievement of your individual goals, the achievement of team goals and the achievement of corporate goals.  Your annual target bonus is subject to review and approval by the aTyr Board of Directors or Compensation Committee of the Board of Directors.  You must be employed by the Company at the time the bonus is paid out to receive the bonus.

 

 

 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

David King, Ph.D.

September 13, 2016

Page two

 

	
 
	
 

 

	
Equity: 
	
As promptly as practicable after commencement of your employment with the Company, and subject to approval by the Board of Directors (or the Compensation Committee of the Board of Directors), you will be granted an option to purchase 145,000 shares of the Common Stock of the Company (the “Option”).  Subject to your continued full-time employment with the Company, the shares subject to the Option shall vest over a four (4) year period from your employment start date, with a one (1) year cliff, such that one-fourth (1/4) of the shares subject to the Option shall vest on the first year anniversary of your employment start date and the remainder of the shares shall thereafter vest in equal monthly installments over the subsequent three (3) years.  The exercise price per share of the Option shall be determined based on the closing price of the Common Stock as reported on NASDAQ on the effective date of the grant.  The specific terms and conditions of your Option will be subject to the terms set forth in a Stock Option Agreement between you and the Company. 

 

	
Severance Policy:
	
Subject to final approval by the Compensation Committee, you will be eligible for aTyr’s Executive Severance and Change in Control Policy.  This policy will include severance provisions for “Not for Cause” separations as well as “Change in Control” separations.  The specifics of the plan will be provided to you.

 

	
Relocation:
	
The Company shall reimburse you for the reasonable, out of pocket expenses that you incur in connection with relocating from the San Francisco area to the San Diego area, up to a maximum amount of (i) up to $20,000 for the movement of your household goods and (ii) up to $24,000 (that would be grossed up to cover tax costs) for commuting expenses (airfare, car rental and temporary housing) for up to 3 months.  Any such reimbursement is subject to your submission of documentation sufficient to substantiate any such expenses and compliance with the Company's expense reimbursement policies and procedures.  Notwithstanding the foregoing, no such reimbursement shall be payable later than the end of the calendar year after the calendar year in which you incurred the expense.  

 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

David King, Ph.D.

September 13, 2016

Page three

 

	
 
	

	
In the event that your employment with the Company is terminated by the Company for cause or you voluntarily resign, in any event within eighteen months after the date that you relocate, you shall no longer be eligible for any such reimbursements and you shall repay to the Company any relocation expenses previously reimbursed by the Company.

 

	

	
For purposes of this letter, your relocation shall be deemed complete on the date you provide the Company written confirmation of your new residence in the San Diego area.

 

	
Benefits:
	
You will be entitled to receive standard medical, life and dental insurance benefits for yourself and your dependents in accordance with Company policy.  Company reserves the right to change or eliminate these benefits on a prospective basis at any time.

 

	
401(k) Plan:
	
You will be eligible to participate in the aTyr Pharma, Inc. 401(k) Savings Plan immediately following the start of your employment.  

 

Vacation & 

	
Sick Time:
	
You will be entitled to accrue 15 days of vacation per year as a Full-Time employee.  You will have 6 days of sick time available each year.

 

	
Holidays:
	
You will be eligible for aTyr’s paid holidays.  The schedule is published prior to the beginning of each calendar year.

 

	
Employment at Will:
	
Your employment will be at-will, which means it may be terminated at any time by you or the Company for any reason, with or without cause, and that your employment is not for any specific period of time.  Any change to the at-will employment relationship must be by a specific, written agreement signed by you and the Company’s Chief Executive Officer.

 

	
 Start Date:
	
Monday, September 26, 2016 as a full-time employee

 

 

As a condition of your employment, you will be required to sign and abide by our Employee Nondisclosure and Assignment Agreement (the “Employee NDA”) when you begin your 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

David King, Ph.D.

September 13, 2016

Page four 

 

employment.  A copy is attached for your reference.  As a condition of your employment, you will also be required to abide by the Company’s code of conduct and other policies applicable to

employees as set forth in the Company’s employee handbook in effect from time to time.  A copy will be made available to you during your employment.  In addition, in order to comply with the Immigration Reform and Control Act of 1986, within three (3) days of your Start Date you will be required to provide sufficient documentation to verify your identity and legal authorization to work in the United States. Please bring with you on your Start Date, the original of one of the documents noted in List A or one document from List B and one document from List C as itemized in the enclosed “Lists of Acceptable Documents”.  If you do not have the originals of any of these documents, please contact me immediately.

 

In the event of any dispute or claim relating to or arising out of your employment relationship with the Company, this agreement, or the termination of your employment with the Company for any reason (including, but not limited to, any claims of breach of contract, defamation, wrongful termination or age, sex, sexual orientation, race, color, national origin, ancestry, marital status, religious creed, physical or mental disability or medical condition or other discrimination, retaliation or harassment), you and the Company agree that all such disputes shall be fully resolved by confidential, binding arbitration conducted by a single arbitrator through the American Arbitration Association (“AAA”) under the AAA’s National Rules for the Resolution of Employment Disputes then in effect, which are available online at the AAA’s website at www.adr.org.  The arbitrator shall permit adequate discovery and is empowered to award all remedies otherwise available in a court of competent jurisdiction and any judgment rendered by the arbitrator may be entered by any court of competent jurisdiction.  By executing this letter, you and the Company are both waiving the right to a jury trial with respect to any such disputes.  Company shall bear the costs of the arbitrator, forum and filing fees.  Each party shall bear its own respective attorney fees and all other costs, unless otherwise provided by law and awarded by the arbitrator.

 

It is aTyr’s policy to respect fully the rights of your previous employers in their proprietary or confidential information.  No employee is expected to disclose, or is allowed to use for aTyr’s  purposes, any confidential or proprietary information he or she may have acquired as a result of previous employment.

 

I am pleased to extend this offer to you and look forward to your acceptance.  Please sign and return the enclosed copy of this offer letter as soon as possible to indicate your agreement with the terms of this offer.  This offer will lapse if not signed and returned by Wednesday, September 14, 2016.   

 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

David King, Ph.D.

September 13, 2016

Page five 

 

 

Once signed by you, this letter, together with the Employee NDA, will constitute the complete agreement between you and the Company regarding employment matters and will supersede all prior written or oral agreements or understandings on these matters.

 

Our mission is to discover life-changing therapies with relentless determination for people with grave maladies where others fall short.  I believe you will be able to make an immediate contribution to this mission and I think you will enjoy the rewards of working for an innovative, fast-paced company.  One of the keys to our success is top people.  We hope you accept our offer to be one of those people.

 

Yours sincerely,

 

 

/s/ John Mendlein

John Mendlein, Ph.D.

Chief Executive Officer

 

Enclosures

 

 

I accept the terms of employment as described in this offer letter dated September 13th 2016 and will start my employment on September 26th.  I confirm that by my start date at aTyr Pharma, Inc. I will be under no contract or agreement with any other entity which would in any way restrict my ability to work at aTyr Pharma, Inc. or perform the functions of my job for aTyr, including, but not limited to, any employment agreement and/or non-compete agreement.

 

/s/ David King  Date September 14th 2016

David King, Ph.D.

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]